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A Meta-Analysis of the Accuracy of
Prostate Cancer Studies Which Use
Magnetic Resonance Spectroscopy as a
Diagnostic Tool
Objective: We aimed to do a meta-analysis of the existing literature to assess
the accuracy of prostate cancer studies which use magnetic resonance spec-
troscopy (MRS) as a diagnostic tool.
Materials and Methods: Prospectively, independent, blind studies were select-
ed from the Cochrane library, Pubmed, and other network databases. The criteria
for inclusion and exclusion in this study referenced the criteria of diagnostic
research published by the Cochrane center. The statistical analysis was adopted
by using Meta-Test version 6.0. Using the homogeneity test, a statistical effect
model was chosen to calculate different pooled weighted values of sensitivity,
specificity, and the corresponding 95% confidence intervals (95% CI). The sum-
mary receiver operating characteristic (SROC) curves method was used to
assess the results.
Results: We chose two cut-off values (0.75 and 0.86) as the diagnostic criteria
for discriminating between benign and malignant. In the first diagnostic criterion,
the pooled weighted sensitivity, specificity, and corresponding 95% CI
(expressed as area under curve [AUC]) were 0.82 (0.73, 0.89), 0.68 (0.58, 0.76),
and 83.4% (74.97, 91.83). In the second criterion, the pooled weighted sensitivity,
specificity, and corresponding 95% CI were 0.64 (0.55, 0.72), 0.86 (0.79, 0.91)
and 82.7% (68.73, 96.68). 
Conclusion: As a new method in the diagnostic of prostate cancer, MRS has a
better applied value compared to other common modalities. Ultimately, large
scale RCT randomized controlled trial studies are necessary to assess its clinical
value. 
rostate cancer has ubiquitously become the second most common cause
of cancer-related deaths in men and poses a growing health problem (1).
Since the 1980s the rate of prostate cancer has increased in significance
every year in China. In Shanghai, the mean annual rate of increase has been over
6.2% (2). Hence, a method is needed to aid in distinguishing patients who have a
clinically indolent prostate cancer (3). The current modalities for evaluation and
diagnosis of prostate cancer include transrectal ultrasound, digital rectal examination
(DRE), prostate specific antigen (PSA), random biopsies of the prostate, and magnetic
resonance imaging (MRI) with an endorectal coil. However, their diagnostic capabili-
ties have not been satisfactory (4). MR spectroscopy (MRS) has been a relatively new
modality in the diagnosis of prostate cancer since the 1980s. The MRS has the ability
to discriminate prostate cancer from the normal peripheral zone based on a reduced
citrate and elevated choline in the cancerous region. The value of citrate as a tissue
marker for differentiation of BPH (benign prostatic hyperplasia) from cancer prostate
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Phas been demonstrated in animal models, cell lines, and
tissue extracts (5, 6). However, there is no systemic assess-
ment on its value when used in a clinical setting. Evidence-
based medicine is an important concept that has been
proven to be a popular and useful method for identifying
and evaluating evidence in producing the guidelines for
medical practice. Here, we provide a meta-analysis for the
review of the published literature for two aims: 1) to assess
the accuracy of the prostate cancer with the the ratio of
(choline + creatine) / citrate detected by MRS and, 2) to
compare the value of two clinical dignostic criteria: cut-off
values 0.75 and 0.86.
MATERIALS AND METHODS
Inclusion and Exclusion Criteria 
The inclusion and exclusion criteria were established
based on the standards of diagnostic research published by
the Cochrane methods group for screening and diagnostic
testing (http://www.Cochrane. org/docs/sadtdocl.htm).
Type of Research
This systematic review includes only prospective
observational studies in which the results of the diagnostic
test of interest were compared with that of a reference
standard - histological biopsy, radical prostatectomy, or
surgery. 
All case reports, letters, reviews, and common reviews
were excluded.
Objective of Original Random Control Test
The objective of this study is to evaluate the value of
MRS in diagnosing prostate cancer. A positive study for a
malignant prostate mass was defined by Kurhanewicz et al.
(6). All scans were read by radiology medicine doctors
which were “blinded” to the patients’ history, clinical
presentation, and physical examination. The studies which
were “blindly read” were not mentioned to be in the
exclusion criteria. Moreover, the subjects had not
previously undergone hormone or radiotherapy before
they underwent an MRI and MRS. The studies without
information on the specificity or sensitivity were excluded.
Search Strategy
The relevant publications were identified in the database
by querying the Medline (http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?), Elsevier, Springer, OVID, CNKI
(China National Knowledge Infrastructure), and Embase
databases by computer from 1994 to 2006. Next, a manual
research of the reference lists cited in the original articles
of the relevant journals had also been done. All medical
subject headings with diagnosis were combined with
words: (carcinoma of prostate OR prostate cancer OR
prostate carcinoma OR prostate tumor) AND diagnosis
AND (MRS OR MR spectroscopic imaging OR magnetic
resonance spectroscopic imaging OR MR spectroscopy OR
magnetic resonance spectroscopy) AND sensitivity AND
specificity. The publication languages were restricted to
English and Chinese and the research subjects were
human. There was no limitation set on the reporting date.
All articles were checked by two independent reviewers
and any disagreement was resolved employing the arbitra-
tion of a third reviewer.
Quality Assessment
According to a hierarchy of evidence in the diagnostic
test studies from the Cochrane methods group (7, 8), only
studies in Grade A (an independent, blind comparison with
reference standard among an appropriate population of
consecutive patients) and Grade B (an independent, blind
comparison with reference standard among an appropriate
population of non-consecutive patients or confined to a
narrow population of study patients) were included in this
review. 
Data Extraction
The common information including the articles’ Grade,
author, published time, number of subjects, mean age,
lesions, and level of PSA. were extracted. Other data such
as true positive value (TP), true negative value (TN), false
positive value (FP), false negative value (FN), sensitivity
(SEN), specificity (SPE), accuracy (ACC), positive likeli-
hood ratio, negative likelihood ratio were also extracted.
Data Analysis and Synthesis
The meta-test software (VERSION 0.9 Joseph Lau, MD-
New England Medical Center, Boston, MA) was used for
the data analysis and synthesis. Group differences between
two diagnosis criteria were considered significant at a p
value of < 0.05 by Fisher’s Exact test.
I) Homogeneity test: Diagnostic meta-analysis achieved
by pooling the results of individual studies. The results
produce a common effect size. As a result, before the data
were pooled and calculated, a test of the homogeneity of
results between the different studies was necessary using
the Q statistic of the Chi-square value test.
2) Statistical model: The statistical model used in the
meta-analysis included a fixed effects model which was
chosen following the determination of the absence of
heterogeneity. Alternatively, if the heterogeneity test
failed, a random effects model was selected to analyze the
data (9).
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selected to calculate pooled weighted values of sensitivity
and specificity with the corresponding 95% CI (95%
Confidence Interval). According to Moses et al. (10), we
established a linear regression equation between D and S
as follows: D = logit (TPR) - logit (FPR); S = logit (TPR) +
logit (FPR) (TPR - true positive rate, FPR - false positive
rate). The model is D = A + BS (A is the regression
intercept and B is the regression coefficient). A and B can
be calculated by the least square method. Moreover, the
model can be transformed back to the conventional axes of
TPR against FPR, which facilitates the determination of a
SROC curve to calculate the area under the SROC. If the
curve is closer to top-left corner, the area under curve
(AUC) is larger, which means that the diagnosis is more
accurate.  
RESULTS 
The Characteristics of Included Articles
According to criteria set in the index words, a total of
140 papers were screened from the above-mentioned
databases. However, only 7 studies remained after taking
into account the inclusion and exclusion criteria. Among
these articles, two were of Grade A, whereas the other five
were of Grade B (Table 1). In clinical practice, the classifi-
cation system described by Kurhanewicz et al. (6) was
often used: normal - a voxel of signal intensity ratios of
(choline + creatine) / citrate lower than 0.75; suspicious -
between 0.75 and 0.86; definitive tumor - above this
threshold. To calculate the sensitivity and specificity,
descriptive statistical data (TP, TN, FP, and FN) were
determined by using two dichotomized rating systems: one
with a voxel ratio of less than 0.75 which was not
determined to be cancer, as opposed to a voxel ratio
greater than 0.75 which represented a finding of cancer.
While another cut-off value was 0.86. Five studies used a
diagnostic value of 0.75 as a cut-off criteria (Table 2), as
opposed to five studies, which used a diagnostic cut-off
value of 0.86 (Table 3).
Data Analysis
The homogeneity test showed: Q1 = 37.20, P1 < 0.01, Q2
= 23.17, P2 < 0.01. Therefore, in these two groups, the
random effects models was used for the meta-analysis.
Forest plots for two groups were constructed and the
pooled weighted sensitivity, specificity, and corresponding
95% CI were calculated (Fig. 1, Table 4). 
Summary Receiver Operating Characteristic Curve
Because SROC can inflect a non-linear relationship
between the sensitivity and specificity simultaneously, it
was better used (18) to assess the accuracy of the diagnos-
tic tests. Here we drew and analyzed SROC and calculated
Wang et al.
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Table 1. Baseline of Included Articles
Author PY MA NP Le ML/BL PSA ng/mL-1 Gleason score Grade
Ullrich GM (11) 2001 60.6±6.2 48 242 152/90 UN* UN B
Juyoung AJ (12) 2004 56 (44-69) 22 387 306/81 5.9 (2.2-17.2) 6.6 (5-8) B
Wefer AE (13) 2000 58 (46-77) 47 250 162/250 UN 6.1 (4-8) B
Juergen S (14) 1999 60.2±7.1 53 234 155/79 8.2±5.0 5.3±1.0 (4-10) B
Kyle KY (15) 1999 60±7 53 106 24/82 8±56 ±1 (4-10) B
Yuen JS (16) 2004 64.5 (58, 69) 24 296 15/281 UN UN A
Prando A (17) 2005 63.3 (45, 75) 42 384 52/296 6.8 (4.1, 15.3) UN A
Note.─ PY = published year, MA = mean age, NP = number of patients, Le = lesions, ML = number of malignant lesions, BL = number of benign lesions, 
UN = un-reported information, PSA = prostate specimen antigen
Table 2. Diagnostic Value of 0.75 as Criterion
Author SEN % SPE % ACC % PPV % NPV % TP TN FP FN
Ullrich GM (11) 0.80 0.61 0.73 0.78 0.65 122 055 35 30
Juyoung AJ (12)* 90.0 73.2 76.8 47.7 96.5 073 219 80 08
93.0 69.2 74.2 44.9 97.2 075 207 92 06
Wefer AE (13) 0.76 0.57  0.69 0.76 0.56  123 050 38 39
Juergen S (14) 0.86 0.49 0.74 0.77 0.65 134 039 40 21
Kyle KY (15) 0.50 0.91 0.76 0.63 0.86 012 075 071 2
Note.─ *Results from two radiologists. SEN = sensitivity , SPE = specificity, ACC = accuracy, PPV = positive predictive value, NPV = negative predictive 
value, TP = true positive value, TN = true negative value, FP = false positive value, FN = false negative valueAUC for these two groups (Figs. 2, 3).
Statistical Testing 
The pooled weighted sensitivity of the first criterion was
higher 0.82 (0.73, 0.89) than the second 0.64 (0.55, 0.72),
in which the p-value was < 0.0001, Chi-square value =
57.13 However, its specificity is lower [0.68 (0.58, 0.76)
vs. 0.86 (0.79, 0.91)] than, a p-value < 0.0001, Chi-square
value = 118.30. However, the difference between the two
AUCs was not significant, 83.40 versus 82.70 (if the differ-
ence between two AUCs was greater than 5%, the
diagnostic performance between two objects had statistics
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Table 3. Diagnostic Value of 0.86 as Criterion
Author SEN % SPE % ACC % PPV %  NPV % TP TN FP FN
Ullrich GM (11) 0.53 0.73 60.74 77.14 48.18 81 066 24 71
Juyoung AJ (12)* 0.69 89.3 0.085 063.6 091.4 56 267 32 25
0.64 84.6 080.3 053.1 089.7 52 253 46 29
Scheidler J (14) 0.63 0.75 0.067 0.083 0.051 98 059 20 57
Yuen JS (16) 38.5 94.3 091.9 023.8 097.1 06 266 15 09
Prando A (17) 0.86 0.89 0.089 0.058 0.097 44 264 32 08
Note.─ *Results from two radiologists. SEN = sensitivity , SPE = specificity, ACC = accuracy, PPV = positive predictive value, NPV = negative predictive 
value, TP = true positive value, TN = true negative value, FP = false positive value, FN = false negative value
A
Fig. 1. Forest plots of two groups of
diagnostic criteria. 
A, B. First diagnostic criterion (A) second
diagnostic criterion (B). Block plot mean
values of sensitivity or 100-specificty.
Transversal line cross plots represent the
95% CI. Shorter lines indicate that
studies are more accurate. Bottom plots
represent pooled weighted values. 
Bsignificance, which suggested that the accuracy would be
same) (Table 4). 
DISCUSSION
In the diagnosis of prostate cancer, conventional modali-
ties have their limitations. DRE misses up to 45% of all
cancers subsequently detected on subsequent biopsies.
Further, cancers detected by DRE are in an advanced stage
in up to 50% of cases. Using a PSA cut-off value of 4
ng/ml as an indication of carcinoma of the prostate, up to
25% of men with cancer may be missed. In addition, the
positive predictive value of the test is only 30% in
asymptomatic men (4). An MRI performed using an
endorectal coil is unsuitable as a primary diagnostic tool
for detecting prostate cancer due to its low specificity and
low positive predictive value (19); although, the accuracy
of MRI staging for stages B and C is 77% and there is a
high sensitivity of detection for extraprostatic tumor
extension and seminal vesicle infiltration (20, 21). To date,
the histopathologic examinations of biopsy tissue remain
the gold standard for diagnosis of prostate cancer.
However, this method only results in a sensitivity of 50%
and specificity of 82%. In these cases, malignancies are
Wang et al.
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Table 5. Hierarchy of Evidence for Diagnostic Accuracy on Cochrane Methods
Level Description
A Independent, blind comparison with reference standard among appropriate population of consecutive patients.
B Independent, blind comparison with reference standard among appropriate population of non-consecutive patients 
or confined to narrow population of study patients.
C Independent, non-blind comparison with reference standard among appropriate population of consecutive patients.
D Independent, non-blind comparison with reference standard among appropriate population of non-consecutive 
patients or confined to narrow population of study patients.
E Independent, blind comparison among appropriate population of patients; however, reference standard is not 
applied to all study patients.
F Reference standard not applied independently or, expert opinion with no explicit critical appraisal based on physiology, 
bench research, or first principles.
Table 4. Meta-analysis of Two Criteria
Heterogeneity (Q) SEN % (95% CI) SPE % (95% CI) AUC % (95% CI) PLR (95% CI) NLR (95% CI)
0.75 Q1 = 37.20 82 (73, 89) 68 (58, 76) 83.40 (74.97, 91.83) 2.64 (2.39, 2.92) 0.26 (0.22, 0.31)
0.86 Q2 = 23.17 64 (55, 72) 86 (79, 91) 82.70 (68.73, 96.68) 7.24 (6.04, 8.69) 0.37 (0.33, 0.42)
Note.─ SEN = sensitivity, SPE = specificity, AUC = area under curve, PLR = positive likelihood ratio, NLR = negative likelihood ratio
Fig. 2. Summary receiver operating characteristic curve of first
diagnostic criterion - 0.75. Area under curve represents accuracy
of diagnosis. Larger area, greater level of accuracy. Area under
curve is 83.4% (74.97, 91.83).
Fig. 3. Summary receiver operating characteristic curve of
second diagnostic criterion - 0.86. Area under curve is 82.7%
(68.73, 96.68).easily overlooked because of their multi-focal and hetero-
geneous nature, which happens in as many as 85% of
patients (22, 23). It has been reported that after a radical
prostatectomy, the biopsy-determined result increased in
as many as 54% of patients (24). Therefore, an accurate
and noninvasive way of determining prostate cancer is
needed to improve the ability to define subsets of patients
in which a cure is possible and necessary.
The MRS can detect a resonance spectrum from different
chemical compounds in tissues, which in turn, reveals
structural information about the chemical compound as
well as the metabolic information of the tissues. In normal
prostate tissue, high levels of citrate are found. However,
in the case of prostate cancer, citrate levels diminish or are
undetectable because of a conversion from citrate-produc-
ing to citrate-oxidating metabolism. Moreover, the choline
level is elevated due to a high phospholipids cell
membrane turnover rate in the proliferating malignant
tissue. Hence, the method for depicting tumors is based on
an increased (choline + creatine) / citrate ratio (22).
A meta-analysis is a statistical analysis that combines or
integrates the results of several independent studies consid-
ered to be combinable. The reliability of the results
depends on the quality of the included studies and whether
the result of the analysis is reliable. According to
Cochrane’s methods of screening and diagnosis (Table 5),
the suggested quality in the five levels of diagnostic
procedures were (Grade A and Grade B) for analysis by
two reviewers’ independent evaluation, which may lead to
a selection bias with more information. All the studies we
used for this study are prospective observational (indepen-
dent), blind comparisons with a reference standard, in
which radiologists scan and diagnose the patients after the
scientific experiment design. According to our selection
criteria this meta-analysis included only 7 studies out of the
many reviewed articles. One reason for this low number is
that MRS has been used in diagnosing prostate cancer for
only a few years and related studies are scarce. Another
factor is that the quality of these studies on the basis of
inclusion in meta-analyses are not high. Case in point, only
two studies qualified as Grade A, whereas the other five
studies included subjects that all had prostate cancer, which
represented a selection bias of the subjects, though the
MRS tests the peak of choline, citrate, and creatine in the
different voxels of whole prostates. Moreover, the two
radiologists are unaware of which patient has prostate
cancer. According to Table 1, our intentions were to
analyze the homogeneity of the basic information of all
studies including PSAs, Gleason grades which may affect
the assessment of the results (6). However, it is impossible
to achieve this because data is not integral. 
In some studies detected voxels are determined by
biopsy sites. However, a biopsy is inaccurate because
prostate cancer is multi-focal and heterogeneous in nature,
and it is limited in examining all cancers, sites, and grades
(24). Hence, their (15, 16) positive results are much smaller
than the negative results and the sensitivity is not so
reliable. 
According to Kristen et al. (25) who measured the MR
spectroscopic imaging, and the ratio of prostate tumor for
(Cho +Cr) / Cit ratio. A positive correlation was found
with the pathologic Gleason score. His data indicated that
in the diagnosis, cancer with a Gleason score of 3 +3, the
MR spectroscopic imaging tumor detection sensitivity was
44.4%, and the sensitivity increased to 89.5% in cancers
with a Gleason score of more than 8. Thus, a large propor-
tion of tumors with a Gleason score of 6 and under 6 did
not generate abnormal voxel metabolite ratios. One
possible explanation for this finding is that these tumors
tended to be smaller, thereby permitting a volume averag-
ing with noncancerous tissue. Another is that low-grade
tumors (below 6) may be missed, due to slight alterations
in citrate and choline levels. In all studies except that of
Prando et al. (17) we have not talked about tumor or
volume, so we didn’t further analyze it. 
We use SROC to analyze our meta-analysis results. The
advantage of SROC curves is that the curves may be tested
for symmetry and therefore can be determined if a
subgroup analysis is appropriate. A disadvantage of SROC
curves is that if a large variability is present between
subgroups, the goodness of fit using SROC curves will be
limited (26). In this meta-analysis, we have only compared
the value of two criteria. The two AUCs are similar;
however, their sensitivity and specificity possess noticeable
differences. Hence, the combination of the two criteria
may improve the accuracy in clinical use.
In China, the cut-off value for diagnosing prostate
tumors has not yet been determined. Different researchers
have studied different values. Wang et al. (27) and Li et al.
(28) compared the value of MRS. However, their study
results were compared to biopsy and non-pathologic
results, which yielded a different set of outcomes. At the
present time, we still need large samples and multi-center
studies to increase the confidence in the results.
In conclusion, we could not analyze the literature with a
more reasonable option than we have now, due to poor
reporting in the primary studies and small quantity of
studies. Here, we supply just the primary assessment of the
value for MRS in clinic. More prospective studies will be
needed to consummate it.
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